{"id":"NCT02104817","sponsor":"AstraZeneca","briefTitle":"Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia","officialTitle":"A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-30","primaryCompletion":"2020-05-27","completion":"2020-05-27","firstPosted":"2014-04-04","resultsPosted":"2021-07-28","lastUpdate":"2021-08-17"},"enrollment":13078,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)"],"interventions":[{"type":"DRUG","name":"EpanovaÂ® (omega-3 carboxylic acids)","otherNames":["omega-3 carboxylic acids"]},{"type":"DRUG","name":"corn oil control","otherNames":[]}],"arms":[{"label":"EPANOVA","type":"EXPERIMENTAL"},{"label":"Corn oil","type":"ACTIVE_COMPARATOR"}],"summary":"The study is a randomized, double-blind, placebo-controlled (corn oil), parallel group design that will enroll approximately 13,000 patients with hypertriglyceridemia and low HDL and high risk for CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for approximately 3-5 years as determined when the number of MACE outcomes is reached.","primaryOutcome":{"measure":"The Composite of Major Adverse Cardiovascular Events (MACE)","timeFrame":"From the date of randomization and up to completion of the end-of-treatment visit (Month 60) or at study closure","effectByArm":[{"arm":"Epanova","deltaMin":785,"sd":null},{"arm":"Placebo","deltaMin":795,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.837"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":684,"countries":["United States","Australia","Belgium","Canada","China","Czechia","Denmark","Estonia","Hungary","Italy","Japan","Lithuania","Mexico","Netherlands","New Zealand","Poland","Russia","South Africa","South Korea","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["33993205","33190147"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5881C00004&amp;attachmentIdentifier=be55f883-e635-4760-b404-758aa7dd6106&amp;fileName=redacted_CSP.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5881C00004&amp;attachmentIdentifier=5b7552b6-b71b-4a3b-8abf-513efc223986&amp;fileName=redacted_SAP.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":2259,"n":6532},"commonTop":["Diarrhoea","Nausea","Type 2 diabetes mellitus","Diabetes mellitus","Nasopharyngitis"]}}